Lamivudine (3TC)(lam ah vew’ den)
Epivir, Epivir-HBV
PREGNANCY CATEGORY C
Drug Classes
Antiviral
Reverse transcriptase inhibitor
Therapeutic Actions
Nucleoside analogue inhibitor of HIV reverse transcriptase via DNA viral chain termination and HBV polymerase.
Indications
Treatment of HIV infection in combination with other antiretroviral drugs
Treatment of chronic hepatitis B (Epivir-HBV) with active liver inflammation
Contraindications and Cautions
Contraindicated with life-threatening allergy to any component.
Use cautiously with compromised bone marrow function, impaired renal function, hepatic impairment, obesity, pregnancy, lactation.
Available Forms
Tablets—100 (Epivir–HBV); 150, 300 mg (Epivir); oral solution—5 mg/mL (Epivir–HBV), 10 mg/mL (Epivir)
Dosages
Adults
Hepatitis B: 100 mg PO daily.
Adults and patients 16 yr and older
HIV infection: 150 mg PO bid or 300 mg/day PO as a single dose in combination with other antiretroviral drugs.
Pediatric patients
HIV infection: 3 mo–16 yr: 4 mg/kg PO bid; up to a maximum of 150 mg bid.
or:
Children weighing 14–21 kg: 75 mg (one-half tablet) PO bid.
Children weighing more than 21 kg but less than 30 kg: 75 mg (one-half tablet) PO in the morning and then 150 mg (1 tablet) PO in the evening.
Children weighing 30 kg or more: 150 mg (1 tablet) PO bid.
Hepatitis B:
2–17 yr: 3 mg/kg PO daily up to a maximum of 100 mg daily.
Patients with impaired renal function
HIV infection:
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
